Micron downgraded, Five Below upgraded: Wall Street's top analyst calls

Upgrades Summary - Five Below (FIVE) upgraded to Outperform from Market Perform without a price target, with confidence in its ability to achieve strong comparable store sales growth [2] - Carnival (CCL) upgraded to Overweight from Equal Weight with a price target of $31, down from $33, indicating an attractive risk/reward at current share levels [2] - Tandem Diabetes (TNDM) upgraded to Buy from Hold with a price target of $35, up from $27, due to expectations of significant revenue and profit growth as the company transitions to a Pay/Go model [2] - MoonLake Immunotherapeutics (MLTX) upgraded to Buy from Neutral with a price target of $40, up from $12, as regulatory hurdles for sonelokimab are becoming clearer [2] - Union Pacific (UNP) upgraded to Outperform from In Line with a price target of $262, up from $260, highlighting strong volume growth and robust margins despite merger-related challenges [2]